Self‐Assembled Trispecific T Cell Nanoengagers for Enhanced Cancer Immunotherapy
Small · 2025-12 · 21 (48)
DOI: 10.1002/smll.202504869 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 19.10.2025. Verfasst von Guixi Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Faculty of Medicine, Tianjin University, Tianjin, 300072, China. Hauptthemen laut MEDLINE: Immunotherapy, T-Lymphocytes, Nanoparticles, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Zhejiang Leading Innovation and Entrepreneurship Team.
Abstract (Originalsprache)
Trispecific T cell engagers (Tri‐TCEs) hold significant promise for tumor immunotherapy but face challenges from complex manufacturing and low production yields. Herein, a nanobody‐based trispecific T cell nanoengagers platform, termed Tri‐Nb@FNP is introduced, which leverages the modular and programmable assembly of nanobodies on ferritin nanoparticles (FNP) via SpyTag/SpyCatcher bioconjugation technology. These nanoengagers are designed to target EGFR‐positive triple‐negative breast cancer (TNBC) or HER2 positive breast cancer, alongside CD3 and CD28 on T cells, thereby facilitating precise immune synapse formation. This synergistic interaction robustly enhances T cell activation, proliferation and cytotoxicity, promotes cytotoxic CD8 + T cell infiltration into the tumor microenvironment, and achieves significant tumor suppression both in vitro and in vivo. Tri‐Nb@FNP is thus established as a novel class of Tri‐TCEs, offering a simple and efficient self‐assembly platform to integrate multispecific targeting molecules for advancing cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Life Sciences, Faculty of Medicine, Tianjin University, Tianjin, 300072, China.
- Zhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Basic and Clinical Application of Functional Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Chin…
ORCID-Profile: Juan Li
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Zhejiang Leading Innovation and Entrepreneurship Team
- Pioneer R&D Program of Zhejiang
Zitieren
APA
Zhang, G., Zhang, S., Kang, Y., Zhang, J., Li, Z., Zhu, Y., & Li, J. (2025). Self‐Assembled Trispecific T Cell Nanoengagers for Enhanced Cancer Immunotherapy. Small, 21(48). https://doi.org/10.1002/smll.202504869
Vancouver
Zhang G, Zhang S, Kang Y, Zhang J, Li Z, Zhu Y, et al. Self‐Assembled Trispecific T Cell Nanoengagers for Enhanced Cancer Immunotherapy. Small. 2025;21(48). doi:10.1002/smll.202504869
BibTeX
@article{Zhang2025,
author = {Zhang, Guixi and Zhang, Sen and Kang, Yingqiu and Zhang, Jianfeng and Li, Zheyuan and Zhu, Yingdi and Li, Juan},
title = {Self‐Assembled Trispecific T Cell Nanoengagers for Enhanced Cancer Immunotherapy},
journal = {Small},
year = {2025},
volume = {21},
number = {48},
doi = {10.1002/smll.202504869}
}
EUVIMED